dc.contributor.author
Timm, Sara
dc.contributor.author
Lettau, Marie
dc.contributor.author
Hegermann, Jan
dc.contributor.author
Rocha, Maria Linda
dc.contributor.author
Weidenfeld, Sarah
dc.contributor.author
Fatykhova, Diana
dc.contributor.author
Gutbier, Birgitt
dc.contributor.author
Nouailles, Geraldine
dc.contributor.author
Lopez-Rodriguez, Elena
dc.contributor.author
Hocke, Andreas
dc.contributor.author
Hippenstiel, Stefan
dc.contributor.author
Witzenrath, Martin
dc.contributor.author
Kuebler, Wolfgang M
dc.contributor.author
Ochs, Matthias
dc.date.accessioned
2025-11-19T10:23:20Z
dc.date.available
2025-11-19T10:23:20Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/50418
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-50145
dc.description.abstract
Recent investigations analyzed in depth the biochemical and biophysical properties of the endothelial glycocalyx. In comparison, this complex cell-covering structure is largely understudied in alveolar epithelial cells. To better characterize the alveolar glycocalyx ultrastructure, unaffected versus injured human lung tissue explants and mouse lungs were analyzed by transmission electron microscopy. Lung tissue was treated with either heparinase (HEP), known to shed glycocalyx components, or pneumolysin (PLY), the exotoxin of Streptococcus pneumoniae not investigated for structural glycocalyx effects so far. Cationic colloidal thorium dioxide (cThO(2)) particles were used for glycocalyx glycosaminoglycan visualization. The level of cThO(2) particles orthogonal to apical cell membranes ( estimates stained glycosaminoglycan height) of alveolar epithelial type I (AEI) and type II (AEII) cells was stereologically measured. In addition, cThO(2) particle density was studied by dual-axis electron tomography ( estimates stained glycosaminoglycan density in three dimensions). For untreated samples, the average cThO(2) particle level was & AP; 18 nm for human AEI, & AP; 17 nm for mouse AEI, ≈ AP; 44 nm for human AEII and ≈ AP; 35 nm for mouse AEII. Both treatments, HEP and PLY, resulted in a significant reduction of cThO(2) particle levels on human and mouse AEI and AEII. Moreover, a HEP- and PLY-associated reduction in cThO(2) particle density was observed. The present study provides quantitative data on the differential glycocalyx distribution on AEI and AEII based on cThO(2) and demonstrates alveolar glycocalyx shedding in response to HEP or PLY resulting in a structural reduction in both glycosaminoglycan height and density. Future studies should elucidate the underlying alveolar epithelial cell type-specific distribution of glycocalyx subcomponents for better functional understanding.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
alveolar epithelial glycocalyx
en
dc.subject
thorium dioxide
en
dc.subject
electron tomography
en
dc.subject
lung stereology
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
The unremarkable alveolar epithelial glycocalyx: a thorium dioxide-based electron microscopic comparison after heparinase or pneumolysin treatment
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s00418-023-02211-7
dcterms.bibliographicCitation.journaltitle
Histochemistry and Cell Biology
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.pagestart
83
dcterms.bibliographicCitation.pageend
96
dcterms.bibliographicCitation.volume
160
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
37386200
dcterms.isPartOf.issn
0948-6143
dcterms.isPartOf.eissn
1432-119X